Statins mediate anti- and pro-tumourigenic functions by remodelling the tumour microenvironment

Cell surface marker and intracellular SPC expression was analysed by flow cytometry as described (Kamata et al., 2015, 2020). Primary antibodies used were as follows: anti-mouse CD11b (clone M1/70, Tonbo Biosciences; 1:300), anti-Gr1 (clone RB6-8C5, SouthernBiotech; 1:500), anti-mouse CD11c (clone N418, BioLegend; 1:200), anti-F4/80 (clone BM8, BioLegend; 1:100), anti-Ly6C (clone HK1.4, BioLegend; 1:200), anti-mouse CD45 (clone 30-F11, BioLegend; 1:600), anti-mouse CD4 (clone GK1.5, BioLegend; 1:100), anti-mouse CD8a (clone 53-6.7, BioLegend; 1:200), anti-mouse B220 (clone RA3-6B2, BioLegend; 1:200), anti-mouse CD31 (clone MEK13.3, BioLegend; 1:200) and anti-Sca1 (clone D7, Miltenyi Biotech; 1:300) antibodies. Stromal cell types quantified using this panel were previously described (Kamata et al., 2020). For SPC intracellular staining, surface-stained lung cells were fixed/permeabilised using a BD Cytofix/Cytoperm™ kit (BD Biosciences), according to the manufacturer's instructions, and frozen at −20°C for 24 h. Then, the frozen cells were thawed in a 37°C water bath and stained with an anti-SPC antibody (FL-197, Santa Cruz Biotechnology; 1:100) in BD Perm/Wash™ buffer (BD Biosciences) at 37°C for 45 min followed by AlexaFluor®488-conjugated anti-rabbit antibody (Thermo Fisher Scientific; 1:2000) staining in BD Perm/Wash™ buffer at room temperature for 20 min.

Comments (0)

No login
gif